---
title: "Natco Pharma Says API Unit In Chennai Receives Establishment Inspection Report From U.S. FDA"
description: "Natco Pharma Ltd :NATCO PHARMA - API UNIT IN CHENNAI RECEIVES ESTABLISHMENT INSPECTION REPORT FROM U.S. FDANATCO PHARMA - API UNIT IN CHENNAI RECEIVES EIR FROM U.S. FDANATCO PHARMA - COMPANY RECEIVED "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/275846236.md"
published_at: "2026-02-13T03:48:19.000Z"
---

# Natco Pharma Says API Unit In Chennai Receives Establishment Inspection Report From U.S. FDA

> Natco Pharma Ltd :NATCO PHARMA - API UNIT IN CHENNAI RECEIVES ESTABLISHMENT INSPECTION REPORT FROM U.S. FDANATCO PHARMA - API UNIT IN CHENNAI RECEIVES EIR FROM U.S. FDANATCO PHARMA - COMPANY RECEIVED SEVEN OBSERVATIONSNATCO PHARMA - RECEIVED EIR CLASSIFIED AS VOLUNTARY ACTION INDICATED

Natco Pharma Ltd :

-   NATCO PHARMA - API UNIT IN CHENNAI RECEIVES ESTABLISHMENT INSPECTION REPORT FROM U.S. FDA
-   NATCO PHARMA - API UNIT IN CHENNAI RECEIVES EIR FROM U.S. FDA
-   NATCO PHARMA - COMPANY RECEIVED SEVEN OBSERVATIONS
-   NATCO PHARMA - RECEIVED EIR CLASSIFIED AS VOLUNTARY ACTION INDICATED

### Related Stocks

- [BIB.US - Proshares Ultra Nasdaq Biotech](https://longbridge.com/en/quote/BIB.US.md)
- [IBB.US - iShares Biotechnology ETF](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US - Invesco Biotechnology & Genome ETF](https://longbridge.com/en/quote/PBE.US.md)
- [ARKG.US - Ark Genomic Revolution ETF](https://longbridge.com/en/quote/ARKG.US.md)
- [VHT.US - VG Health](https://longbridge.com/en/quote/VHT.US.md)
- [NGEN.US - NervGen Pharma](https://longbridge.com/en/quote/NGEN.US.md)
- [IHE.US - iShares US Pharma](https://longbridge.com/en/quote/IHE.US.md)
- [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US - First Trust NYSE Arca Biotech Index Fd](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US - VanEck Biotech ETF](https://longbridge.com/en/quote/BBH.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| BREAKINGVIEWS-An $8 bln pharma deal prices patent fears | Gilead Sciences has agreed to acquire Arcellx for $115 per share in cash, plus a contingent value right of $5 per share  | [Link](https://longbridge.com/en/news/276632155.md) |
| AbbVie announces $380m investment in North Chicago API facilities | AbbVie has announced a $380 million investment in its North Chicago API facilities, set to integrate advanced manufactur | [Link](https://longbridge.com/en/news/276714948.md) |
| Recursion to Participate in Upcoming Investor Conferences \| RXRX Stock News | Recursion (Nasdaq: RXRX), a clinical stage TechBio company, announced its participation in several upcoming investor con | [Link](https://longbridge.com/en/news/276602047.md) |
| What To Expect From Elanco’s (ELAN) Q4 Earnings | Elanco (ELAN) is set to report its Q4 earnings this Tuesday. Last quarter, it exceeded revenue expectations with $1.14 b | [Link](https://longbridge.com/en/news/276558679.md) |
| Noble Financial Sticks to Their Buy Rating for Cocrystal Pharma (COCP) | Noble Financial analyst Robert LeBoyer has maintained a Buy rating for Cocrystal Pharma (COCP) with a price target of $6 | [Link](https://longbridge.com/en/news/276629179.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.